Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

American Journal of Medicine

Volumn 129, Issue 6, 2016, Pages 592-599.e1

  Lopes, Renato D ^a   Rao, Meena ^a   Simon, Dajuanicia N ^a   Thomas, Laine ^a   Ansell, Jack ^b   Fonarow, Gregg C ^c   Gersh, Bernard J ^d   Go, Alan S ^e   Hylek, Elaine M ^f   Kowey, Peter ^g   Piccini, Jonathan P ^a   Singer, Daniel E ^h   Chang, Paul ⁱ   Peterson, Eric D ^a   Mahaffey, Kenneth W ^j  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e KAISER PERMANENTE   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anticoagulants; Antiplatelets; Atrial fibrillation; Combined therapy; Coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DABIGATRAN; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; WARFARIN; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; TICLOPIDINE;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PRIORITY JOURNAL; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMORBIDITY; COMPLICATION; HOSPITALIZATION; MARKOV CHAIN; MONTE CARLO METHOD; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS AND NUMERICAL DATA; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; REGISTRIES; STROKE; TICLOPIDINE; WARFARIN;

EID: 84958581820     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.12.026     Document Type: Article

References (29)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study Arch Intern Med 147 1987 1561 1564
2. P.A. Wolf, T.R. Dawber, H.E. Thomas Jr., and et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke Neurology 28 1978 973 977
3. K. Flegel, M. Shipley, and G. Rose Risk of stroke in non-rheumatic atrial fibrillation Lancet 329 1987 526 529
4. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
5. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 e76
6. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Eur Heart J 33 2012 2719 2747
7. ACTIVE Writing Group of the ACTIVE Investigators S. Connolly, J. Pogue, R. Hart, and et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
8. C. van Walraven, R.G. Hart, S. Connolly, and et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators Stroke 40 2009 1410 1416
9. J. Mant, F.D. Hobbs, K. Fletcher, and et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503
10. S. Lee, A.C. Shafe, and M.R. Cowie UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database BMJ Open 1 2011 e000269
11. B.A. Steinberg, S. Kim, J.P. Piccini, and et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Circulation 128 2013 721 728
12. J.H. Alexander, R.D. Lopes, L. Thomas, and et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 35 2014 224 232
13. M.L. Hansen, R. Sørensen, M.T. Clausen, and et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 2010 1433 1441
14. A.L. Dans, S.J. Connolly, L. Wallentin, and et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
15. J.P. Piccini, E.S. Fraulo, J.E. Ansell, and et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 2011 606 612
16. M.C. Fang, A.S. Go, Y. Chang, and et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 2011 395 401
17. G.Y. Lip, R. Nieuwlaat, R. Pisters, and et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
18. B.F. Gage, A.D. Waterman, W. Shannon, and et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
19. R.D. Lopes, A. Starr, C.F. Pieper, and et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes Am J Med 123 2010 134 140
20. R.D. Lopes, L.E. Elliott, H.D. White, and et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial Eur Heart J 30 2009 2019 2028
21. M. Lamberts, G.H. Gislason, J.B. Olesen, and et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention J Am Coll Cardiol 62 2013 981 989
22. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, and et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial Lancet 380 2012 1749 1758
23. C.N. Hess, S. Broderick, J.P. Piccini, and et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients Am Heart J 164 2012 607 615
24. R.D. Lopes, L. Li, C.B. Granger, and et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes Am J Med 125 2012 897 905
25. E.L. Fosbol, T.Y. Wang, S. Li, and et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy Am Heart J 166 2013 864 870
26. W.J. Dewilde, T. Oirbans, F.W. Verheugt, and et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
27. S.B. Freedman, B.J. Gersh, and G.Y. Lip Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation Eur Heart J 36 2015 653 656
28. S.J. Connolly, J. Eikelbloom, C. Joyner, and et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
29. N. Sarafoff, A. Martischnig, J. Wealer, and et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation J Am Coll Cardiol 61 2013 2060 2066